Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Intravenous Doses of FR104 in Healthy Subjects

Trial Profile

Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Intravenous Doses of FR104 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs FR 104 (Primary)
  • Indications Rheumatoid arthritis; Transplant rejection
  • Focus Adverse reactions; First in man
  • Sponsors OSE Immunotherapeutics
  • Most Recent Events

    • 17 Nov 2016 According to OSE Immunotherapeutics media release, positive results were published in the Journal of Immunology.
    • 20 Jul 2016 Status changed from recruiting to completed.
    • 01 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top